The expression and prognostic impact of programmed cell death ligand 1 (PD-L1) in LCNEC were assessed in several studies, and the high frequency of PD-L1 expression could support the use of PD-L1 antibody in the treatment of LCNEC. The gene discussed is CD274; the disease is large cell neuroendocrine carcinoma.